The Health and Care Innovation Expo (Expo NHS) has been for us the occasion to interact with all the main stakeholders of the UK Healthcare environment.
Events like the #Expo17NHS stress the importance of a collaborative approach to medical innovation where the Healthcare System identifies, selects and promotes projects that can bring advantages to the patients and physicians, optimize the utilization of resources and ultimately foster the creation and growth of companies.
NHS England acts as framework, catalyst and connection between the companies’ institutions and patients. As a young medical company, we are benefitting from the NIHR infrastructure and Brain Injury HTC network to find relevant expertise, aggregate partners and suppliers and navigate more broadly through the complex pathway that lies between a prototype and medical product ready to enter the market.
We shared our experience with the NIHR, HTC infrastructures and guests in the workshop “How the NIHR is accelerating technology and innovation in the NHS” on bridging the gap between companies and the NHS to promote medical innovation.
We were honoured by the presence of the Health Minister Lord O’Shaughnessy, who showed interest in the interaction between institutions and private companies through the NIHR and HTC.
“It was a great honor to have the opportunity to present to the Health Minister, Lord O’Shaughnessy, the work we have done with NIHR and the Brain Injury Health Care Technology Cooperative in evolving our technology from a proof of concept stage to an advanced human prototype. Together we bridge the gap to bring this innovation to patients” – Enrico Giuliani
Bringing innovative medical devices to the market is a necessity to improve the quality of care for patients and the Healthcare system, structures like the NIHR and HTC are instrumental in promoting innovation.
Start-ups and more in general SMEs can generate disruptive innovation. It is therefore necessary to support them with an adequate infrastructure and create a smoother pathway to access early clinical validation.
— — — — — —